|
|
|
|
|
|||||||
|
Session 57
Poster Session
Novel Antiretroviral Chemotherapeutic Agents 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 380-T. | A Virus/Cell-Based Assay for the Discovery of Novel Anti-HIV-1 Compounds M. Adelson*1, A. Pacchia1,2, M. Kaul1, R. Rando3, S. Peltz1,3, Y. Ron1, and J. P. Dougherty1 1UMDNJ, Piscataway; 2Rutgers Univ., New Brunswick, NJ; and 3PTC Therapeutics, South Plainfield, NJ
| ||
| 381-T. | Optimization of Multiple Factors in the Discovery and Development of Highly Potent and Broad Spectrum Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors for the Treatment of AIDS K. Das*1, E. Arnold1, A. D. Clark Jr.1, D. W. Ludovici2, M. J. Kukla2, B. DeCorte2, R. W. Kavash2, K. Andries3, R. Pauwels4, M-P. de Béthune4, G. A. E. van't Klooster4, P. Lewi5, S. H. Hughes6, and P. A. J. Janssen5 1Ctr. for Advanced Biotechnology and Med. and Rutgers Univ., Piscataway, NJ; 2Janssen Res. Fndn., Springhouse, PA; 3Janssen Res. Fndn., Beerse, Belgium; 4Tibotec-Virco, Mechelen, Belgium; 5Ctr. for Molecular Design, Janssen Res. Fndn., Vosselaar, Belgium; and 6NCI, NIH, Frederick, MD
| ||
| 382-T. | Combining Antilentiviral Transgenes Potentiates Inhibition of HIV D. Strayer*, F. Branco, J. Landré, M. BouHamdan, F. Shaheen, and R. J. Pomerantz Jefferson Med. Coll., Thomas Jefferson Univ., Philadelphia, PA
| ||
| 383-T. | Targeting HIV Morphogenesis by Inhibiting p55 and gp160 Processing P. Cordelier* and D. Strayer Jefferson Med. Coll., Thomas Jefferson Univ., Philadelphia, PA
| ||
| 384-T. | In Vivo and in Vitro Characterization of GS 7340, an Isopropylalaninyl Phenyl Ester Prodrug of Tenofovir; Selective Intracellular Activation of GS 7340 Leads to Preferential Distribution in Lymphatic Tissues W. Lee*, G. He, A. Mulato, W. Delaney, E. Eisenberg, T. Cihlar, S. Xiong, M. D. Miller, S. Gill, R. Shibata, and C. Gibbs Gilead Sci., Inc., Foster City, CA
| ||
| 385-T. | DPC 817: A Cytidine Nucleoside Analog with Activity against AZT- and 3TC-Resistant Viral Variants S. Erickson-Viitanen*1, R. F. Schinazi2, J. Mellors3, R. Geleziunas1, G. Trainor1, J. T. Wu1, K. Gallagher1, R. Klabe1, M. Otto4, M. Pierce1, and D. E. Martin1 1Bristol-Myers Squibb Co., Wilmington, DE; 2Emory Univ. Sch. of Med., Atlanta and VA Med. Ctr., Decatur, GA; 3Univ. of Pittsburgh, PA; and 4Pharmasset Inc., Tucker, GA
| ||
| 386-T. | BCH-13520, a New Heterosubstituted Nucleoside Analogue, Is an Effective Inhibitor of Drug-Resistant HIV-1 R. C. Bethell*1, B. Allard1, J. M. De Muys1, Z. Gu1, N. Guyen-Ba1, C. Ren1, M. A. Wainberg2, P. McKenna3, and D. L. Taylor4 1Shire BioChem Inc., Laval, QC, Canada; 2Jewish Gen. Hosp., Montreal, QC, Canada; 3Virco Labs., Cambridge, UK; and 4MRC Technology, London, UK
| ||
| 387-T. | Water-Soluble Metalloporphyrins Represent Potent Inhibitors of HIV-1 Replication E. G. Argyris*, J. Fang, and R. J. Pomerantz Dorrance H. Hamilton Labs., Jefferson Med. Coll., Thomas Jefferson Univ., Philadelphia, PA
| ||
| 388-T. | Generation of HIV Variants Resistant to 4'-Ethynyl-2'-Deoxynucleosides: A Role of T165 and M184 in Reverse Transcriptase (RT) Function E. Kodama*1, M. Ikeuchi1, M. Matsuoka1, and H. Mitsuya2 1Inst. for Virus Res., Kyoto Univ. and 2Kumamato Univ. Sch. of Med., Japan
| ||
| 389-T. | 2-Quinolone Derivatives as Potential HIV NNRTI Agents G. Freeman*1, A. Hopkins2, 4, C. Andrews III1, G. Lowell1, 5, S. Gonzales1, 6, J. Cowan1, L. Schaller1, G. Koszalka1, R. Hazen1, L. Boone1, R. Ferris1, K. Creech1, G. Roberts1, S. Short1, K. Weaver1, J. Milton2, D. Stuart2, 3, D. Stammers2, 3, and J. Chan1 1GlaxoSmithKline, Res. Triangle Park, NC; 2Oxford Ctr. for Molecular Sci., Univ. of Oxford, UK; 3Wellcome Trust Ctr. for Human Genetics, Univ. of Oxford, UK; 4Pfizer Central Res., Sandwich, Kent, UK; 5Rush Univ., Chicago, IL; and 6Array Biopharma, Boulder, CO
| ||
| 390-T. | Inhibition of HIV-1 Gene Expression by dsRNA-Mediated Interference W. S. Park*, N. M. Kurosaki, and H. Takaku Chiba Inst. of Technology, Japan
|
